Regenerative medicine company SpinalCyte was issued new patents in Hong Kong and Europe.
Here are three takeaways:
1. The patents are for its lead product CybroCell, an off-the-shelf allogenic human dermal fibroblast product to treat degenerative disc disease.
2. Throughout several clinical trials, CybroCell demonstrated improved pain relief and increased back mobility in patients treated with the fibroblast.
3. SpinalCyte has 35 U.S. and foreign patents issued and 41 patents pending.